Zealand Pharma — Oktober 2022
-
DDB: Our updated SoTP points to a fair value of DKK293 (DKK259) and
primarily reflects de-risking of the glepaglutide project. We raise probability from
65% to 90% plus minor adjustments to peak market estimates for the GLP-2
segment. We now reach a glepaglutide project fair value of DKK127/sh (DKK87). -
Nå, det er åbenbart også en aktie shorterne har overtaget...
-
enig - tak for indsatsen
-
Pensionisten, selvom man er langsigtet, så vil man jo altid gerne prøve at slå markedet. Set i backspejlet, fortryder jeg lidt, at jeg ikke solgte til 190 i fredags for så at købe op langt billigere i dag. Man skal være langsigtet, men man skal også udnytte de muligheder der dukker op. Om det kan betale sig i sidste ende, har jeg desværre ikke lang tid nok erfaring til at kunne sige.
-
Godmorgen.

-
Godmorgen

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind